Company intelligence / Profile preview

ReGenTree

Princeton, New Jersey, United Statesregentreellc.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

ReGenTree has completed Phase 3 clinical trials for its lead product RGN-259 for ophthalmic indications. The company announced additional results in May 2021, and completed the "Last Patient, Last Visit" in November 2020 for one of its clinical trials.

Therapeutic areas: OphthalmologyEndocrinology
Modalities: Synthetic peptideTherapeutic peptide
Industry: Biotech

Drug pipeline

1 asset

timbetasin

Partnerships

GtreeBNT Co., Ltd.RegeneRx Biopharmaceuticals, Inc.

Beyond the preview

Go deeper on ReGenTree.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReGenTree.

Explore the full profile